Literature DB >> 25391120

Regression of takayasu retinopathy after revascularization of occluded branches of the aortic arch by percutaneous angioplasty.

Jayanthi Peter1, George Joseph, Sarada David, Debashish Danda.   

Abstract

PURPOSE: To present a patient with decreased vision because of Takayasu retinopathy who had improvement in vision and regression of retinopathy after percutaneous angioplasty of occluded aortic arch vessels.
METHODS: Interventional case report.
RESULTS: A 37-year-old woman with multiple cerebral infarcts and recurrent seizures was referred with painless progressive reduction in vision in the right eye of few months' duration and left eye for 2 years. Vision was 20/120 in the right eye and perception of light in the left eye. There was mild disk pallor in the right eye, optic atrophy in the left eye, and microaneursyms in both eyes. Angiographic findings were consistent with type I Takayasu arteritis. Angioplasty and stenting was performed initially to the right subclavian and common carotid arteries and to the left subclavian, and left internal carotid arteries 6 weeks later. There was improvement in vision to 20/80 and regression of Takayasu retinopathy in the right eye at 3 months post procedure that improved further to 20/50, 6 months post procedure. Vision, as expected, remained poor in the left eye despite revascularization.
CONCLUSION: Restoration of flow in the aortic arch vessels may result in reversal of ischemic retinal changes in patients with Takayasu retinopathy.

Entities:  

Year:  2013        PMID: 25391120     DOI: 10.1097/ICB.0b013e31828eef72

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  2 in total

1.  Visual outcome after endovascular intervention in Takayasu arteritis.

Authors:  Vaibhav Kumar Jain; Shabari Pal; Vivek Singh; Rini Saha; Kumudini Sharma
Journal:  Taiwan J Ophthalmol       Date:  2022-02-14

2.  Therapeutic Management of Ocular Ischemia in Takayasu's Arteritis: A Case-Based Systematic Review.

Authors:  Yue Zeng; Jianan Duan; Ge Ge; Meixia Zhang
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.